Moonlighting Adenosine Deaminase: A Target Protein for Drug Development

Medicinal Research Reviews

Volumn 35, Issue 1, 2015, Pages 85-125

  Cortés, Antoni ^a   Gracia, Eduard ^a   Moreno, Estefania ^a   Mallol, Josefa ^a   Lluís, Carme ^a   Canela, Enric I ^a   Casadó, Vicent ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adenosine deaminase; Adenosine receptors; Allosteric modulator; CD26; Moonlighting proteins

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE DEAMINASE 1; ADENOSINE DEAMINASE 2; ADENOSINE RECEPTOR; DIPEPTIDYL PEPTIDASE IV; ISOENZYME; MOONLIGHTING PROTEIN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOSINE DEAMINASE DEFICIENCY; ALLOSTERISM; ARTICLE; AUTOIMMUNE DISEASE; BLACKFAN DIAMOND ANEMIA; CATALYSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; CRYSTAL STRUCTURE; DEPRESSION; ENZYME ACTIVITY; ENZYME STRUCTURE; FIBROMYALGIA; HEART DISEASE; HEREDITARY HEMOLYTIC ANEMIA; HUMAN; ILLUMINATION; IMMUNE SYSTEM; INFLAMMATION; MENINGITIS; MULTIPLE SCLEROSIS; NONHUMAN; PANIC; PATHOLOGY; PHYSICAL CHEMISTRY; PROTEIN FUNCTION; PROTEIN QUATERNARY STRUCTURE; PURINE METABOLISM; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THYROID DISEASE; TUBERCULOSIS; ANIMAL; DRUG DESIGN; DRUG EFFECTS;

ADENOSINE DEAMINASE; ANIMALS; DRUG DESIGN; HUMANS;

EID: 84915779253     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21324     Document Type: Article

References (398)

1. Conway EJ, Cooke R. The deaminases of adenosine and adenylic acid in blood and tissues. Biochem J 1939;33:479-492.
2. Brady T. Adenosine deaminase. Biochem J 1942;36:478-484.
3. Boison D. Adenosine kinase: Exploitation for therapeutic gain. Pharmacol Rev 2013;65:906-943.
4. Fredholm BB, Johansson S, Wang YW. Adenosine and the regulation of metabolism and body temperature. Adv Pharmacol 2011;61:77-94.
5. Fredholm BB, Ijzerman AP, Jacobson KA, Linden J, Muller CE. International Union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 2011;63:1-34.
6. Vallon V, Osswald H. Adenosine receptors and the kidney. Handb Exp Pharmacol 2009;193:443-470.
7. Persson P, Hansell P, Palm F. Adenosine A2 receptor-mediated regulation of renal hemodynamics and glomerular filtration rate is abolished in diabetes. Adv Exp Med Biol 2013;765:225-230.
8. Van Linden A, Eltzschig HK. Role of pulmonary adenosine during hypoxia: Extracellular generation, signaling and metabolism by surface adenosine deaminase/CD 26. Expert Opin Biol Ther 2007;7:1437-1447.
9. Brown RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol 2008;153:S446-S456.
10. Takahashi T, Otsugoro K, Ohta T, Ito S. Adenosine and inosine release during hypoxia in the isolated spinal cord of neonatal rats. Br J Pharmacol 2010;161:1806-1816.
11. Cicala C, Ialenti A. Adenosine signaling in airways: Toward a promising antiasthmatic approach. Eur J Pharmacol 2013;714:522-525.
12. Urmaliva VB, Church JE, Coupar IM, RoseMeyer RB, Pouton CW, White PJ. Cardioprotection induced by adenosine A1 receptor agonists in a cardiac cell ischemia model involves cooperative activation of adenosine A2A and A2B receptors by endogenous adenosine. J Cardiovasc Pharmacol 2009;53:424-433.
13. Eltzschig HK, Bonney SK, Eckle T. Attenuating myocardial ischemia by targeting A2B adenosine receptors. Trends Mol Med 2013;19:345-354.
14. Mills JH, Kim DG Krenz A Chen JF, Bynoe MS. A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis. J Immunol 2012;188:5713-5722.
15. Antonioli L, Blandizzi C, Pacher P, Haskó G. Immunity, inflammation and cancer: A leading role for adenosine. Nat Rev Cancer 2013;13:842-857.
16. Kumar V. Adenosine as an endogenous immunoregulator in cancer pathogenesis: Where to go? Purinergic Signal 2013;9:145-165.
17. Ribeiro JA, Sebastiao AM. Caffeine and adenosine. J Alzheimer Dis 2010;20:S3-S15.
18. Lopes LV, Sebastiao AM, Ribeiro JA. Adenosine and related drugs in brain diseases: Present and future in clinical trials. Curr Top Med Chem 2011;11:1087-1101.
19. Boison D. Adenosine as a neuromodulator in neurological diseases. Curr Opin Pharmacol 2008;8:2-7.
20. Sperlagh B, Vizi ES. The role of extracellular adenosine in chemical neurotransmission in the hippocampus and basal ganglia: Pharmacological and clinical aspects. Curr Top Med Chem 2011;11:1034-1046.
21. Maia L, de Mendonca A. Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 2002;9:377-382.
22. Selley ML. Increased homocysteine and decreased adenosine formation in Alzheimer's disease. Neurol Res 2004;26:554-557.
23. Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 2002;58:1154-1160.
24. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF. Adenosine, adenosine A2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 2009;15:406-413.
25. Morelli M, Carta AR, Kachroo A, Schwarzschild MA. Pathophysiological roles for purines: Adenosine, caffeine and urate. Prog Brain Res 2010;183:183-208.
26. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl) 1997;133:107-120.
27. Wardas J. Potential role of adenosine A2A receptors in the treatment of schizophrenia. Front Biosci 2008;13:4071-4096.
28. Reggio R, Pezzola A, Popoli P. The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Res 1999;831:315-318.
29. Popoli P, Blum D, Domenici MR, Burnouf S, Chern Y. A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Curr Pharm Des 2008;14:1500-1511.
30. Ribeiro JA, Sebastiao AM, de Mendonca A. Participation of adenosine receptors in neuroprotection. Drug News Perspect 2003;16:80-86.
31. Rebola N, Porciuncula LO, Lopes LV, Richardson PJ, Oliveira CR, Cunha RA. Long-term effect of convulsive behavior on the density of adenosine A1 and A2A receptors in the rat cerebral cortex. Epilepsia 2005;46:159-165.
32. Boison D. Adenosine dysfunction in epilepsy. Glia 2012;60:1234-1243.
33. Maldonado R, Blendy JA, Tzavara E, Gass P, Roques BP, Hanoune J, Schutz G. Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science 1996;273:657-659.
34. Manzoni O, Pujalte D, Williams J, Bockaert J. Decreased presynaptic sensitivity to adenosine after cocaine withdrawal. J Neurosci 1998;18:7996-8002.
35. Knapp CM, Foye MM, Cottam N, Ciraulo DA, Kornetsky C. Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol Biochem Behav 2001;68:797-803.
36. Brown RM, Short JL. Adenosine A(2A) receptors and their role in drug addiction. J Pharm Pharmacol 2008;60:1409-1430.
37. Ruby CL, Adams CA, Knight EJ, Nam HW, Choi DS. An essential role for adenosine signalling in alcohol abuse. Curr Drug Abuse Rev 2010;3:163-174.
38. Wu M, Sahbaie P, Zheng M, Lobato R, Boison D, Clark JD, Peltz G. Opiated-induced changes in brain adenosine levels and narcotic drug responses. Neuroscience 2013;228:235-242.
39. Mackiewicz M, Nikonova EV, Zimmerman JE, Galante RJ, Zhang L, Cater JR, Geiger JD, Pack AI. Enzymes of adenosine metabolism in the brain: Diurnal rhythm and the effect of sleep deprivation. J Neurochem 2003;85:348-357.
40. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-264.
41. Boison D, Chen JF, Fredholm BB. Signaling and function in glial cells. Cell Death Differ 2010;17:1071-1082.
42. Hawryluk JM, Ferrari LL, Keating SA, Arrigoni E. Adenosine inhibits glutamatergic input to basal forebrain cholinergic neurons. J Neurophysiol 2012;107:2769-2781.
43. Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013;19:355-367.
44. Augusto E, Matos M, Sevigny J, El-Tayeb A, Bynoe MS, Muller CE, Cunha RA, Chen JF. Ecto-5'-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions. J Neurosci 2013;33:11390-11399.
45. Elsherbiny NM, Naime M, Ahmad S, Elsherbini AM, Mohammad S, Fulzele S, El-Remessy AB, Al-Gayyar MM, Eissa LA, El-Shistawy MM, Han G, White R, Haroldo TF, Liou GI. Potential roles of adenosine deaminase-2 in diabetic retinopathy. Biochem Biophys Res Commun 2013;436:355-361.
46. Zavialov AV, Yu X, Spillman D, Lauvau G, Zavialov AV. Structural basis for the growth factor activity of human adenosine deaminase ADA2. J Biol Chem 2010;285:12367-12377.
47. Maier SA, Galellis JR, McDermid HE. Phylogenetic analysis reveals a novel protein family closely related to adenosine deaminase. J Mol Evol 2005;61:776-794.
48. Rosemberg DB, Rico EP, Guidoti MR, Dias RD, Souza DO, Bonan CD, Bogo MR. Adenosine deaminase-related genes: Molecular identification, tissue expression pattern and truncated alternative splice isoform in adult zebrafish (Danio rerio). Life Sci 2007;81:1526-1534.
49. Schinkmanova M, Votruba I, Holy A. N6-methyl-AMP aminohydrolase activates N6-substituted purine acyclic nucleoside phosphonates. Biochem Pharmacol 2006;71:1370-1376.
50. Schinkmanova M, Votruba I, Shibata R, Han B, Liu X, Cihlar T, Holy A. Human N6-methyl-AMP/DAMP aminohydrolase (abacavir 5'-monophosphate deaminase) is capable of metabolizing N6-substituted purine acyclic nucleoside phosphonates. Collect Czech Chem Commun 2008;73:275-291.
51. 6-substituted purine or 2-aminopurine nucleoside monophosphates. J Med Chem 2011;54:5902-5914.
52. Frey CR, Andrei G, Votruba I, Cannizzaro C, Han B, Fung W, Hung M, Liu X, Geleziunas R, Fiten P, Opdenakker G, Snoeck R, Cihlar T. Mutations in adenosine deaminase-like (ADAL) protein confer resistance to the antiproliferative agents N6-cyclopropyl-PMEDAP and GS-9219. Anticancer Res 2013;33:1899-1912.
53. Ratech H, Thorbecke GJ, Meredith G, Hirschhorn R. Comparison and possible homology of isozymes of adenosine deaminase in aves and humans. Enzyme 1981;26:74-84.
54. Zavialov AV, Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J 2005;391:51-57.
55. Ratech H, Hirschhorn R. Serum adenosine deaminase in normals and in a patient with adenosine deaminase deficient severe combined immunodeficiency. Clin Chim Acta 1981;115:341-347.
56. Niedzwicki JG, Abernethy DR. Structure-activity relationships of ligands of human plasma adenosine deaminase 2. Biochem Pharmacol 1991;41:1615-1624.
57. Ungerer JP, Oosthuizen HM, Bissbort SH, Vermaak WJ. Serum adenosine deaminase isoenzymes and diagnostic application. Clin Chem 1992;38:1322-1326.
58. Iwaki-Egawa S, Yamamoto T, Watanabe Y. Human plasma adenosine deaminase 2 is secreted by activated monocytes. Biol Chem 2006;387:319-321.
59. Conlon BA, Law WR. Macrophages are a source of extracellular adenosine deaminase-2 during inflammatory responses. Clin Exp Immunol 2004;138:14-20.
60. Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G. Human adenosine deaminase 2 induces differentiation of monocytes and stimulates proliferation of T helper cells and macrophages. J Leuk Biol 2010;88:279-290.
61. Gorguner M, Cerci M, Gorguner I. Determination of adenosine deaminase activity and its isoenzymes for diagnosis of pleural effusions. Respirology 2000;5:321-324.
62. Riazi MA, Brinkman-Mills P, Nguyen T, Pan H, Phan S, Ying F, Roe BA, Tochigi J, Shimizu Y, Minoshima S, Shimizu N, Buchwald M, McDermid HE. The human homolog of insect-derived growth-factor, CECR1, is a candidate gene for features of cat eye syndrome. Genomics 2000;64:277-285.
63. Agarwal RP, Spector T, Parks RE Jr. Tight-binding inhibitors-IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol 1977;26:359-367.
64. Muraoka T, Katsuramaki T, Shiraishi H, Yokoyama MM. Automated enzymatic measurement of adenosine deaminase isoenzyme activities in serum. Anal Biochem 1990;187:268-272.
65. Cristalli G, Costanzi S, Lambertucci C, Lupidi G, Vittori S, Volpini R, Camaioni E. Adenosine deaminase: Functional implications and different classes of inhibitors. Med Res Rev 2001;21:105-128.
66. Mardanyan S, Sharoyan S, Antonyan A, Armenyan A, Cristalli G, Lupidi G. Tryptophan environment in adenosine deaminase. I: Enzyme dodification with N-bromosuccinimide in the presence of adenosine and EHNA analogs. Biochim Biophys Acta 2001;1546:185-195.
67. Andreasyan NA, Hairapetyan HL, Sargisova YG, Mardanyan SS. ADA2 isoform of adenosine deaminase from pleural fluid. FEBS Lett 2005;579:643-647.
68. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 2000;6:15-19.
69. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78.
70. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22:657-682.
71. Van der Weyden MB, Kelley WN. Adenosine deaminase and immune function. Br J Haematol 1976;34:159-165.
72. Chechik BE, Schrader WP, Minowada J. An immunomorphologic study of adenosine deaminase distribution in human thymus tissue, normal lymphocytes, and hematopoietic cell lines. J Immunol 1981;126:1003-1007.
73. Petersen MB, Tranebjaerg L, Tommerup N, Nygaard P, Edwards H. New assignment of the adenosine deaminase gene locus to chromosome 20q13 × 11 by study of a patient with interstitial deletion 20q. J Med Genet 1987;24:93-96.
74. Daddona PE, Shewach DS, Kelley WN, Argos P, Markham AF, Orkin SH. Human adenosine deaminase. cDNA and complete primary amino acid sequence. J Biol Chem 1984;259:12101-12106.
75. Kelly MA, Vestling MM, Murphy CM, Hua S, Sumpter T, Fenselau C. Primary structure of bovine adenosine deaminase. J Pharm Biomed Anal 1996;14:1513-1519.
76. Yeung CY, Ingolia DE, Roth DB, Shoemaker C, Al-Ubaidi MR, Yen JY, Ching C, Bobonis C, Kaufman RJ, Kellems RE. Identification of functional murine adenosine deaminase cDNA clones by complementation in Escherichia coli. J Biol Chem 1985;260:10299-10307.
77. Niitsu N, Yamaguchi Y, Umeda M, Honma Y. Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2'-deoxycoformycin and 2'-deoxyadenosine: Association with dATP-dependent activation of caspase-3. Blood 1998;92:3368-3375.
78. Aldrich MB, Blacburn MR, Kellems RE. The importance of adenosine deaminase for lymphocyte development and function. Biochem Biophys Res Commun 2000;272:311-315.
79. Aldrich MB, Chen W, Blackburn MR, Martinez-Valdez H, Datta SK, Kellems RE. Impaired germinal center maturation in adenosine deaminase deficiency. J Immunol 2003;171:5562-5570.
80. Blackburn MR, Kellems RE. Adenosine deaminase deficiency: Metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol 2005;86:1-41.
81. Franco R, Pacheco R, Gatell JM, Gallart T, Lluís C. Enzymatic and extraenzymatic role of adenosine deaminase 1 in T-cell-dendritic cell contacts and in alterations of the immune function. Crit Rev Immunol 2007;27:495-509.
82. Ghaemi Oskouie FG, Shameli A, Yang A, Desrosiers MD, Mucsi AD, Blacburn MR, Yang Y, Santamaria P, Shi Y. High levels of adenosine deaminase on dendritic cells promote autoreactive T cell activation and diabetes in nonobese diabetic mice. J Immunol 2011;186:6798-6806.
83. Antonioli L, Colucci R, La Motta C, Tuccori M, Awward O, Da Settimo F, Blandizzi C, Fornai M. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr Drug Target 2012;13:842-862.
84. Akkari R, Burbiel JC, Hockemeyer J, Müller CE. Recent progress in the development of adenosine receptor ligands as anti-inflammatory drugs. Curr Top Med Chem 2006;6:1375-1399.
85. Valentine WN, Paglia DE, Tartaglia AP, Gilsanz F. Hereditary hemolytic anemia with increased red cell adenosine deaminase (45- to 70-fold) and decreased adenosine triphosphate. Science 1977;195:783-785.
86. Glader BE, Backer K, Diamond LK. Elevated erythrocyte adenosine deaminase activity in congenital hypoplastic anemia. N Engl J Med 1983;309:1486-1490.
87. Chottiner EG, Ginsburg D, Tartaglia AP, Mitchell BS. Erythrocyte adenosine deaminase overproduction in hereditary haemolytic anemia. Blood 1989;74:448-453.
88. Dianzani I, Garelli E, Ramenghi U. Diamond-Blacfan anemia: An overview. Pediatr Drugs 2000;2:345-355.
89. Orfali KA, Ohene-Abuakwa Y, Ball SE. Diamond Blackfan anaemia in the UK: Clinical and genetic heterogeneity. Br J Haematol 2004;125:243-252.
90. Fargo JH, Kratz CP, Giri N, Savage SA, Wong C, Backer K, Alter BP, Glader B. Erythrocyte adenosine deaminase: Diagnostic value for Diamond-Blackfan anemia. Br J Hemathol 2013;160:547-554.
91. Pérez-Rodríguez E, Jiménez-Castro D. The use of adenosine deaminase and adenosine deaminase isoenzymes in the diagnosis of tuberculous pleuritis. Curr Opin Pulm Med 2000;6:259-266.
92. Choi SH, Kim YS, Bae IG, Chung JW, Lee MS, Kang JM, Ryu J, Woo JH. The possible role of cerebrospinal fluid adenosine deaminase activity in the diagnosis of tuberculous meningitis in adults. Clin Neurol Neurosurg 2002;104:10-15.
93. Valdes L, Pose A, San Jose E, Martinez-Vazquez JM. Tuberculous pleural effusions. Eur J Intern Med 2003;14:77-88.
94. Zemlin AE, Burgess LJ, Carstens ME. The diagnostic utility of adenosine deaminase isoenzymes in tuberculous pleural effusions. Int J Tuberc Lung Dis 2009;13:214-220.
95. Krenke R, Korczynski P. Use of pleural fluid levels of adenosine deaminase and interferon gamma in the diagnosis of tuberculous pleuritis. Curr Opin Pulm Med 2010;16:367-375.
96. Garcia-Zamalloa A, Taboada-Gomez J. Diagnostic accuracy of adenosine deaminase and lymphocyte proportion in pleural fluid for tuberculous pleurisy in different prevalence scenarios. PLoS One 2012;7:e38729.
97. Hitoglou S, Hatzistilianou M, Gougoustamou D, Athanassiadou F, Kotsis A, Catriu D. Adenosine deaminase activity and its isoenzyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumathol 2001;20:411-416.
98. Saghiri R, Ghashghai N, Movaseghi S, Pourshafiri P, Jalifar S, Bidhendi MA, Ghazizadeh L, Ebrahimi-Rad M. Serum adenosine deaminase activity in patients with systemic lupus erythematosus: A study based on ADA1 and ADA2 isoenzyme pattern. Rheumatol Int 2012;32:1633-1638.
99. Maor I, Rainis T, Lanir A, Lavy A. Adenosine deaminase activity in patients with Crohn's disease: Distinction between active and nonactive disease. Eur J Gastroenterol Hepatol 2011;23:598-602.
100. Nakamachi Y, Koshiba M, Nakazawa T, Hatachi S, Saura R, Kurosaka M, Kusaka H, Kumagai S. Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts. Arthritis Rheum 2003;48:668-674.
101. Becker LV, Rosa CS, Souza Vdo C, Bagatini MD, Casali EA, Leal CA, da Silva JC, Moretto MB, Pinheiro Fde V, Morsch VM, Schetinger MR, Leal DB. Activities of enzymes that hydrolyze adenine nucleotides in platelets from patients with rheumatoid arthritis. Clin Biochem 2010;43:1096-1100.
102. Dos Santos Jaques JA, Becker LV, Souza VD, Bertoldo TM, de Vargas Pinheiro K, Morsch VM, Schetinger MR, Leal DB. Activities of enzymes that hydrolyze adenine nucleotides in lymphocytes from patients with rheumatoid arthritis. Cell Biochem Funct 2013;31:395-399.
103. Zamani B, Jamali R, Jamali A. Serum adenosine deaminase may predict disease activity in rheumatoid arthritis. Rheumatol Int 2012;32:1967-1975.
104. Tang R, Ma Ch, Dong JZ, Liu XP, Liu X. Does adenosine deaminase play a key role in coronary artery disease. Med Hypotheses 2006;67:371-374.
105. Asakura M, Asanuma H, Kim J, Liao Y, Nakamaru K, Fujita M, Komamura K, Isomura T, Furukawa H, Tomoike H, Kitakaze M. Impact of adenosine receptor signalling and metabolism on pathophysiology in patients with chronic heart failure. Hypertens Res 2007;30:781-787.
106. Bagatini MD, Martins CC, Gasparetto D, Spanevello RM, Becker LV, Rosa CS, Battisti V, Belle L, Gonçalves JF, Schetinger MRC, dos Santos RB, Oliveira LZ, Morsch VM. Enzymes that hydrolyze adenine nucleotides in patients with ischemic heart disease. Clin Chim Acta 2011;412:159-164.
107. Niedzwicki JG, Mayer KH, Abushanab E, Abernethy DR. Plasma adenosine deaminase 2 is a marker for human immunodeficiency virus-1 seroconversion. Am J Hematol 1991;37:152-155.
108. Valenzuela A, Blanco J, Callebaut C, Jacotot E, Lluis C, Hovanessian AG, Franco R. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. J Immunol 1997;158:3721-3729.
109. Chittiprol S, Satishchandra P, Bhimasenarao RS, Rangaswamy GR, Sureshbabu SV, Subbakrishna DK, Satish KS, Desai A, Ravi V, Shetty KT. Plasma adenosine deaminase activity among HIV1 Clade C seropositives: Relation to CD4 T cell population and antiretroviral therapy. Clin Chim Acta 2007;377:133-137.
110. Khodadadi I, Abdi M, Ahmadi A, Wahedi MS, Menbari S, Lahoopour F, Rahbari R. Analysis of serum adenosine deaminase (ADA) and ADA1 and ADA2 isoenzyme activities in HIV positive and HIV-HBV co-infected patients. Clin Biochem 2011;44:980-983.
111. Karbownik M, Brzezianska E, Zasada K, Lewinski A. Expression of genes for certain enzymes of pyrimidine and purine salvage pathway in peripherals blood leukocytes collected from patients with Graves' or Hashimoto's disease. J Cell Biochem 2003;89:550-555.
112. Kociel G, Stanojevic G, Nagomi A, Brankovic B, Pavlovicl D. Diagnostic importance of adenosine deaminase activity for progression and invasion of human colon tumours. Med Biol 2003;10:76-78.
113. Ibis M, Koklu S, Yilmaz FM, Basar O, Yilmaz G, Yuksel O, Yildirim E, Ozturk ZA. Serum adenosine deaminase levels in pancreatic diseases. Pancreatology 2007;7:526-530.
114. Rai B, Kaur J, Jacobs R, Arnand SC. Adenosine deaminase in saliva as a diagnostic marker of squamous cell carcinoma of tongue. Clin Oral Invest 2011;15:347-349.
115. Mandapathil M, Szczepanski M, Harasymczuk M, Ren J, Cheng D, Jackson EK, Gorelik E, Johnson J, Lang S, Whiteside TL. CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4 (+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunology 2012;1:659-669.
116. Roberts EL, Roberts OT. Plasma adenosine deaminase isoform 2 in cancer patients undergoing chemotherapy. Br J Biomed Sci 2012;69:11-13.
117. Battisti V, Maders LD, Bagatini MD, Battisti IE, Belle LP, Santos KF, Maldonado PA, Thome GR, Schetinger MR, Morsch VM. Ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP) and adenosine deaminase (ADA) activities in prostate cancer patients: Influence of Gleason score, treatment and bone metastasis. Biomed Pharmacother 2013;67:203-208.
118. Zanini D, Schmatz R, Pelinson LP, Pimentel VC, da Costa P, Cardoso AM, Martins CC, Shetinger CC, Baldissareli J, do Carmo Araujo M, Oliveira L, Chiesa J, Morsch VM, Leal DB, Schetinger MR. Ectoenzymes and cholinesterase activity and biomarkers of oxidative stress in patients with lung cancer. Mol Cell Biochem 2013;374:137-148.
119. Vivekanandhan S, Soundararaian CC, Tripathi M, Maheshwari MC. Adenosine deaminase and 5' nucleotidase activities in peripheral blood T cells of multiple sclerosis patients. Neurochem Res 2005;30:453-456.
120. Spanevello RM, Mazzanti CM, Schmartz R, Thome G, Bagatini M, Correa M, Rosa C, Stefanello N, Belle LP, Moretto MB, Oliveira L, Morsch VM, Schetinger MR. The activity and expression of NTPDase is altered in lymphocytes of multiple sclerosis patients. Clin Chim Acta 2010;411:210-214.
121. Spanevello RM, Mazzanti CM, Bagatini M, Correa M, Schmartz R, Stefanello N, Thome G, Morsch VM, Becker L, Belle L, de Oliveira L, Schetinger MR. Activities of the enzymes that hydrolize adenine nucleotides in platelets from multiple sclerosis patients. J Neurol 2010;257:24-30.
122. Belagavi AC, Shalini M. Cerebrospinal fluid C reactive protein and adenosine deaminase in meningitis in adults. J Assoc Physicians India 2011;59:557-560.
123. Guieu R, Guedj E, Giorgi R, Dousset A, Tuzzolino V, By Y, Leveque JM, Peragut JC, Regis J, Ruf J, Fenouillet E, Roussel P. High cell surface CD26-associated activities and low plasma adenosine concentration in fibromyalgia. Ann Rheum Dis 2012;71:1427-1428.
124. Herken H, Gurel A, Selek S, Armutcu F, Ozen ME, Bulut M, Kap O, Yumru M, Savas HA, Akyol O. Adenosine deaminase, nitric oxide, superoxide dismutase and xanthine oxidase in patients with major depression: Impact of antidepressant treatment. Arch Med Res 2007;38:247-252.
125. Herken H, Akyol O, Yilmaz HR, Tutkun H, Savas HA, Ozen ME, Kalenderoglu A, Gulec M. Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: Alterations by antidepressant treatment. Hum Psychopharmacol 2006;21:53-59.
126. Ozdemir O, Selvi Y, Ozkol H, Tuluce Y, Besiroglu L, Aydin A. Comparison of superoxide dismutase, glutathione peroxidase and adenosine deaminase activities between respiratory and nocturnal subtypes of patients with panic disorder. Neuropsychobiology 2012;66:244-251.
127. Blaese RM1, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 1995;270:475-480.
128. Hirschhorn R, Candotti F. Primary immunodeficiency diseases. In: Ochs HD, Smith CIE, Puck JM, Eds. Immunodeficiency due to Defects on Purine Metabolism. Oxford, UK: Oxford University Press; 2006. p 169-196.
129. Gaspar HB. Bone marrow transplantation and alternatives for adenosine deaminase deficiency. Immunol Allergy Clin N Am 2010;30:221-236.
130. Hershfield MS. Genotype is an important determinant of phenotype in adenosine deaminase deficiency. Curr Opin Immunol 2003;15:571-577.
131. Cohen A, Hirschhorn R, Horowiz SD, Rubinstein A, Polmar SK, Hong R, Martin DW Jr. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci USA 1978;75:472-476.
132. Resta T, Thompson LF. SCID: The role of adenosine deaminase deficiency. Immunol Today 1997;18:371-374.
133. Hashikawa, T., Hooker SW, Maj JG, Knott-Craig CJ, Takedachi M, Murakami S, Thompson LF. Regulation of adenosine receptor engagement by ecto-adenosine deaminase. FASEB J 2004;18:131-133.
134. Hershfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 2005;35:25-30.
135. Sokolic R, Maric I, Garabedian E, Hanson IC, Dodds M, Buckley R, Issekutz AC, Kamani N, Shaw K, Tan B, Bali P, Hershfield MS, Kohn DB, Wayne AS, Candotti F. Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood 2011;118:2688-2694.
136. Ratech H, Greco MA, Gallo G, Rimoin DL, Kamino H, Hirschhorn R. Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal and chodro-osseus tissue alterations. Am J Pathol 1985;120:157-169.
137. Bollinger ME, Arredondo Vega FX, Santisteban I, Schwarz K, Hershfield MS, Lederman HM. Hepatic dysfunction as a complication of adenosine deaminase deficiency. N Engl J Med 1996;334:1367-1371.
138. Rogers MH, Lwin R, Fairbanks L, Gerritsen B, Gaspar HB. Cognitive and behavioural abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr 2001;139:44-50.
139. Hönig M, Albert MH, Sculz A, Sparber-Sauer M, Schütz C, Belohradsky B, Güngor T, Rojewski MT, Bode H, Pannicke U, Lippold D, Schwarz K, Debatin KM, Hershfield MS, Friedrich W. Patients with adenosine deaminase surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 2007;109:3595-3602.
140. Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood 2009;114:3524-3532.
141. Cavazzana-Calvo M, Dal-Cortivo L, André-Schmutz I, Hacein-Bey Abina S, Fischer A. Cell therapy for inherited diseases of the hematopoietic system. CR Biol 2007;330:538-542.
142. Serana F, Sottini A, Chiarini M, Zanotti C, Ghidini C, Lanfranchi A, Notarangelo LD, Caimi L, Imberti L. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J Immunol 2010;185:7713-7722.
143. Hassan A, Booth C, Brightwell A, Allwood Z, Veys P, Rao K. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood 2012;120:3615-3624.
144. Chan B, Wara, D, Bastian J, Hershfield MS, Bohnscak J, Azen CG, Parkman R, Weinberg K, Kohn DB. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol 2005;117:133-143.
145. Gaspar HB, Cooray S, Gilmour KC, Parsley KR, Zhang F, Adams S, Bjorkegren E, Bayford J, Brown L, Davies EG, Veys P, Fairbanks L, Bordon V, Petropoulou T, Kinnon C, Thrasher AJ. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011;3:97ra80.
146. Gaspar HB. Gene therapy for ADA-SCID. Defining the factors for successful outcome. Blood 2012;120:3628-3629.
147. Ferrua F, Brigida I, Aiuti A. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Curr Opin Allergy Clin Immunol 2010;10:551-556.
148. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene theraps for SCID. Nat Immunol 2010;11:457-460.
149. Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, Choi C. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency. Clinical comparison of retroviral vectors and treatment plans. Blood 2012;120:3635-3646.
150. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, Aiuti A. Gene therapy for primary immunodeficiencies. Part 1. Curr Opin Immunol 2012;24:580-584.
151. Montiel-Equihua CA, Thrasher AJ, Gaspar HB. Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency. Curr Gene Ther 2012;12:57-65.
152. Sauer AV, Morbach H, Brigida I, Ng YS, Aiuti A, Meffre E. Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. J Clin Invest 2012;122:2141-2152.
153. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy of primary T cell immunodeficiencies. Gene 2013;525:170-173.
154. Terasaka T, Kinoshita T, Kuno M, Nakanishi I. A highly potent non-nucleoside adenosine deaminase inhibitor: Efficient drug discovery by intentional lead hybridization. J Am Chem Soc 2004;126:34-35.
155. Terasaka T, Okumura H, Tsuji K, Kato T, Nakanishi I, Kinoshita T, Kato Y, Kuno M, Seki N, Naoe Y, Inoue T, Tanaka K, Nakamura K. Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. J Med Chem 2004;47:2728-2731.
156. Terasaka T, Kinoshita T, Kuno M, Seki N, Tanaka K, Nakanishi I. Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors. J Med Chem 2004;47:3730-3743.
157. Da Settimo F, Primofiore G, La Motta C, Taliani S, Simorini F, Marini AM, Mugnaini L, Lavecchia A, Novellino E, Tuscano D, Martini C. Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3, 4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modelling studies. J Med Chem 2005;48:5162-5174.
158. Terasaka T, Tsuji K, Kato T, Nakanishi I, Kinoshita T, Kato Y, Kuno M, Inoue T, Tanaka K, Nakamura K. Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: Predicting enzyme conformational change and metabolism. J Med Chem 2005;48:4750-4753.
159. Ujjinamatada RK, Phatak P, Burger AM, Hosmane RS. Inhibition of adenosine deaminase by analogues of adenosine and inosine, incorporating a common hetercyclic base, 4(7)-amino-6(5)H-imidazol[4, 5-d]pyridazin-7(4)one. J Med Chem 2008;51:694-698.
160. LaMotta C, Sartini S, Mugnaini L, Salerno S, Simorini F, Taliani S, Marini AM, Da Settimo F, Lavecchia A, Novellino E, Antonioli L, Fornai M, Blandizzi C, Del Tacca M. Exploiting the pyrazolo[3, 4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors. J Med Chem 2009;52:1681-1692.
161. Gillerman I, Fischer B. Investigations into the origin of the molecular recognition of several adenosine deaminase inhibitors. J Med Chem 2011;54:107-121.
162. Limongelli V, Marinelli L, Cosconati S, La Motta C, Sartini S, Mugnaini L, Da Settimo F, Novellino E, Parrinello M. Sampling protein motion and solvent effect during ligand binding. Proc Natl Acad Sci USA 2012;109:1467-1472.
163. Robak T. Purine nucleoside analogues in the treatment of myeloid leukemias. Leuk Lymphoma 2003;44:391-409.
164. Dearden CE. Role of single-agent purine analogues in therapy of peripheral T-cell lymphomas. Semin Hematol 2006;43:S22-S26.
165. Fortune AF, Kelly K, Sargent J, O'Brien D, Quinn F, Cahwick N, Flynn C, Conneally E, Browne P, Crotty GM, Thornton P, Vanderberghe E. Large granular lymphocyte leukemia: Natural history and response to treatment. Leuk Lymphoma 2010;51:839-845.
166. Antonioli L, Fornai M, Colucci R, Ghisu N, Da Settimo F, Natale G, Kastsiuchenka O, Duranti E, Virdis A, Vassalle C, La Motta C, Mugnaini L, Breschi MC, Blandizzi C, Del Taca M. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp Ther 2007;322:435-442.
167. Kinoshita T, Nishio N, Nakanishi I, Sato A, Fujii T. Structure of bovine adenosine deaminase complexed with 6-hydroxy-1, 6-dihydropurine riboside. Acta Crystallogr 2003;D59:299-303.
168. Luo M, Singh V, Taylor EA, Schramm VL. Transition-state variation in human, bovine and Plasmodium falciparum adenosine deaminases. J Am Chem Soc 2007;129:8008-8017.
169. Grever MR. Hairy cell leukemia: A successful model for experimental therapeutics-Pentostatin and new ideas. Leuk Lymphoma 2011;52:25-28.
170. Johnston JB. Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leuk Lymphoma 2011; 52:43-45.
171. Hisatome I. Adenosine and cardioprotection in chronic heart failure: Genes and protein expression. Hypertens Res 2007;30:757-758.
172. Abd-Elfattah AS, Aly H, Hanan S, Wechsler AS. Myocardial protection in beating heart cardiac surgery: I-Pre- or postconditioning with inhibition of es-ENT1 nucleoside transporter and adenosine deaminase attenuates post-MI reperfusion-mediated ventricular fibrillation and regional contractile dysfunction. J Thorac Cardiovasc Surg 2012;144:250-255.
173. Law WR, Valli VE, Conlon BA. Therapeutic potencial for transient inhibition of adenosine deaminase in systemic inflammatory response syndrome. Crit Care Med 2003;31:1475-1481.
174. Kayhan N, Funke B, Conzelmann NO, Winkler H, Hofer S, Steppan J, Schmidt H, Bardenheuer H, Vahl CF, Weigand MA. The adenosine deaminase inhibitor erytro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: A prospective, randomised laboratory investigation. Crit Care 2008;12:R125-R135.
175. Pimentel VC, Gomes JL, Zanini D, Abdalla FH, da Costa P, Gonçalves JF, Duarte MM, Moretto MB, Morsch VM, Schetinger MR. Evaluation of acetylcholinesterase and adenosine deaminase activities in brain and erythrocytes and proinflammatory cytokine levels in rats submitted to neonatal hypoxia-ischemia model. Mol Cell Biochem 2013;378:247-255.
176. Wilson DK, Quiocho FA. A pre-transition-state mimic of an enzyme: X-ray structure of adenosine deaminase with bound 1-deazaadenosine and zinc-activated water. Biochemistry 1993;32:1689-1694.
177. Wang Z, Quiocho FA. Complexes of adenosine deaminase with two potent inhibitors: X-ray structures in four independent molecules at pH of maximum activity. Biochemistry 1998;37:8314-8324.
178. Kinoshita T, Tada T, Nakanishi I. Conformational change of adenosine deaminase during ligand-exchange in a crystal. Biochem Biophys Res Commun 2008;373:53-57.
179. Wilson DK, Rudolph FB, Quiocho FA. Atomic structure of adenosine deaminase complexed with a transition-state analog: Understanding catalysis and immunodeficiency mutations. Science 1991;252:1278-1284.
180. Cooper BF, Sideraki V, Wilson DK, Domínguez DY, Clark SW, Qiocho FA, Rudolph FB. The role of divalent cations in structure and function of murine adenosine deaminase. Protein Sci 1997;6:1031-1037.
181. 2+ on the structure and stability of murine adenosine deaminase. J Phys Chem B 2010;114:16156-16165.
182. Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph 1996;14:33-38.
183. Sharff AJ, Wilson DK, Chang Z, Quiocho FA. Refined 2.5A structure of murine adenosine deaminase at pH 6.0. J Mol Biol 1992;226:917-921.
184. Kinoshita T, Nakanishi I, Terasaka T, Kuno M, Seki N, Warizaya M, Matsumura H, Inoue T, Takano K, Adachi H, Mori Y, Fujii T. Structural basis of compound recognition by adenosine deaminase. Biochemistry 2005;44:10562-10569.
185. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H., Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res 2000;28:235-242.
186. Trincavelli ML. Unveiling the binding mode of adenosine deaminase inhibitors to the active site of the enzyme: Implication for rational drug design. Purinergic Signal 2013;9:1-3.
187. Frick L, Wolfenden R, Smal E, Baker DC. Transition-state stabilization by adenosine deaminase: Structural studies of its inhibitory complex with deoxycoformycin. Biochemistry 1986;25:1616-1621.
188. Kurz LC, Moix L, Riley MC, Frieden C. The rate of formation of transition-state analogues in the active site of adenosine deaminase is encounter-controlled: Implications for the mechanism. Biochemistry 1992;31:39-48.
189. Agarwal RP, Sagar SM, Parks RE Jr. Adenosine deaminase from human erythrocytes: Purification and effects of adenosine analogs. Biochem Pharmacol 1975;24:693-701.
190. Nair V, Wiechert RJ. Substrate specificity of adenosine deaminase-Function of the 5'-hydroxyl group of adenosine. Bioorg Chem 1980;9:423-433.
191. Mikhailopoulo IA, Wiedner H, Cramer F. Substrate specificity of adenosine deaminase: The role of the substituents at the 2'- and 3'-carbons of adenine nucleosides, of their configuration and of the conformation of the furanose ring. Biochem Pharmacol 1981;30:1001-1004.
192. Porter DJ, Spector T. Alternative substrates for calf intestinal adenosine deaminase. A pre-steady-state kinetic analysis. J Biol Chem 1993;268:2480-2485.
193. Ford H Jr., Dai F, Mu L, Siddiqui MA, Nicklaus MC, Anderson L, Márquez VE, Barchi JJ Jr. Adenosine deaminase prefers a distinct sugar ring conformation for binding and catalysis: Kinetic and structural studies. Biochemistry 2000;39:2581-2592.
194. Anderson E, Britt BM. The stability curve of bovine adenosine deaminase is bimodal. J Biomol Struct Dyn 2002;20:375-380.
195. Shu Q, Frieden C. Urea-dependent unfolding of murine adenosine deaminase: Sequential destabilization as measured by 19F NMR. Biochemistry 2004;43:1432-1439.
196. Shu Q, Frieden C. Relation of enzyme activity to local/global stability of murine adenosine deaminase: 19F NMR studies. J Mol Biol 2005;345:599-610.
197. Ho MC, Cassera MB, Madrid DC, Ting LM, Tyler PC, Kim K, Almo SC, Schramm VL. Structural and metabolic specificity of methylthiocoformycin for malarial adenosine deaminases. Biochemistry 2009;48:9618-9626.
198. Spector T. Progress curve analysis of adenosine deaminase-catalyzed reactions. Anal Biochem 1984;138:242-245.
199. Martínez C, Zumalacárregui JM, Díez V. Bovine skeletal muscle adenosine deaminase: Kinetic and thermodynamic studies. Enzyme 1988;39:199-204.
200. Spivey DB, Snow LD. Adenosine deaminase activity of chicken erythrocyte and heart cytosols. Int J Biochem 1989;21:645-648.
201. Franco R, Aran JM, Canela EI. Fitting integrated enzyme rate equations to progress curves with the use of a weighting matrix. Biochem J 1991;274:509-511.
202. Saboury AA, Divsalar A, Jafari GA, Moosavi-Movahedi AA, Housaindokht MR, Hakimelahi GH. A product inhibition study on adenosine deaminase by spectroscopy and calorimetry. J Biochem Mol Biol 2002;35:302-305.
203. Pei L, Xie L, Lin Q, Ling X, Guan Z, Yang Z. Studies on the adenosine deaminase-catalyzed conversion of adenosine and nucleoside prodrugs by different capillary electrophoresis modes. Anal Biochem 2011;414:131-1370.
204. Agarwal RP. Inhibitors of adenosine deaminase. Pharmacol Ther 1982;17:399-429.
205. Lupidi G, Cristalli G, Marmocchi F, Riva F, Grifantini M. Inhibition of adenosine deaminase from several sources by deaza derivatives of adenosine and EHNA. J Enzyme Inhib 1985;1:67-75.
206. Centelles JJ, Franco R Bozal J. Purification and partial characterization of brain adenosine deaminase: Inhibition by purine compounds and by drugs. J Neurosci Res 1988;19:258-267.
207. Singh LS, Sharma R. Purification and characterization of intestinal adenosine deaminase from mice. Mol Cell Biochem 2000;204:127-134.
208. Castro C, Britt BM. Binding thermodynamics of the transition state analogue coformycin and of the ground state analogue 1-deazaadenosine to bovine adenosine deaminase. J Enzyme Inhib 2001;16:217-232.
209. Alrokayan S. Purification and characterization of adenosine deaminase from camel skeletal muscle. Int J Biochem Cell Biol 2002;34:1608-1618.
210. Ali EM. Fasciola gigantica: Purification and characterization of adenosine deaminase. Exp Parasitol 2008;119:285-290.
211. Pornbanlualap S, Chalopagorn P. Adenosine deaminase from Streptomyces coelicolor: Recombinant expression, purification and characterization. Protein Expr Purif 2011;78:167-173.
212. Ivanov A, Matsumura I. The adenosine deaminases from Plasmodium vivax and Plasmodium falciparum exhibit surprising differences in ligand specificity. J Mol Graph Model 2012;35:43-48.
213. Ting LM, Mwakingwe A, Birck MR, Ringia EA, Bench G, Madrid DC, Tyler PC, Evans GB, Furneaux RH, Schramm VL, Kim K. Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins. J Biol Chem 2005;280:9547-9554.
214. Larson ET, Deng W, Krumm BE, Napuli A, Mueller N, Van Voorhis WC, Buckner FS, Fan E, Lauricella A, DeTitta G, Luft J, Zucker F, Hol WG, Verlinde CL, Merritt EA. Structures of substrate- and inhibitor-bound adenosine deaminase from a human malaria parasite show a dramatic conformational change and shed light on drug selectivity. J Mol Biol 2008;381:975-988.
215. Tyler PC, Taylor EA, Fröhlich RF, Schramm VL. Synthesis of 5'-methylthio coformycins: Specific inhibitors for malarial adenosine deaminase. J Am Chem Soc 2007;129:6872-6879.
216. Wilson DK, Quiocho FA. Crystallographic observation of a trapped tetrahedral intermediate in a metalloenzyme. Nat Struct Biol 1994;1:691-694.
217. Bhaumik D, Medin J, Gathy K, Coleman MS. Mutational analysis of active site residues of human adenosine deaminase. J Biol Chem 1993;268:5464-5470.
218. Mohamedali KA, Kurz LC, Rudolph FB. Site-directed mutagenesis of active site glutamate-217 in mouse adenosine deaminase. Biochemistry 1996;35:1672-1680.
219. Sideraki V, Wilson DK, Kurz LC, Quiocho FA, Rudolph FB. Site-directed mutagenesis of histidine 238 in mouse adenosine deaminase: Substitution of histidine 238 does not impede hydroxylate formation. Biochemistry 1996;35:15019-15028.
220. Sideraki V, Mohamedali KA, Wilson DK, Chang Z, Kellems RE, Quiocho FA, Rudolph FB. Probing the functional role of two conserved active site aspartates in mouse adenosine deaminase. Biochemistry 1996;35:7862-7872.
221. Gleeson MP, Burton NA Hillier IH. Prediction of the potency of inhibitors of adenosine deaminase by QM/MM calculations. Chem Commun 2003;17:280-281.
222. Wu XH, Zou GL, Quan, JM, Wu YD. A theoretical study on the catalytic mechanism of Mus musculus adenosine deaminase. J Comput Chem 2010;31:2238-2247.
223. Franco R, Canela EI, Bozal J. Heterogeneous localization of some purine enzymes in subcellular fractions of rat brain and cerebellum. Neurochem Res 1986;11:423-435.
224. Franco R, Valenzuela A, Lluís C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev 1998;161:27-42.
225. Yegutkin GG, Henttinen T, Samburski SS, Spychala J, Jalkanen S. The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells. Biochem J 2002;367:121-128.
226. Blackburn MD, Kellems RE. Adenosine deaminase deficiency: Metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol 2005;86:1-41.
227. Bielat K, Tritsch GL. Ecto-enzyme activity of human erythrocyte adenosine deaminase. Mol Cell Biochem 1989;11:135-142.
228. Da Silva AS, Schafer AS, Aires AR, Tonin AA, Pimentel VC, Oliveira CB, Zanini D, Schetinger MR, Lopes ST, Leal ML. E-ADA activity in erythrocytes of lambs experimentally infected with Haemonchus contortus and its possible functional correlations with anemia. Res Vet Sci 2013;95:1026-1030.
229. Pacheco R, Martinez-Navio JM, Lejeune M, Climent N, Oliva H, Gatell JM, Gallart T, Mallol J, Lluis C, Franco R. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci USA 2005;102:9583-9588.
230. Desrosiers MD, Cembrola KM, Fakir MJ, Stephens LA, Jama FM, Shameli A, Mehal WZ, Santamaria P, Shi Y. Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol 2007;179:1884-1892.
231. Ginés S, Mariño M, Mallol J, Canela EI, Morimoto C, Callebaut C, Hovanessian A, Casadó V, Lluis C, Franco R. Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction. Biochem J 2002;361:203-209.
232. Saura CA, Mallol J, Canela EI, Lluis C, Franco R. Adenosine deaminase and A1 adenosine receptors internalize together following agonist-induced receptor desensitization. J Biol Chem 1998;273:17610-17617.
233. Torvinen M, Ginés S, Hillion J, Latini S, Canals M, Ciruela F, Bordoni F, Staines W, Pedata F, Agnati LF, Lluís C, Franco R, Ferré S, Fuxe K. Interactions among adenosine deaminase, adenosine A(1)receptors and dopamine D(1) receptors in stably cotransfected fibroblast cells and neurons. Neuroscience 2002;113:709-719.
234. Souza Vdo C, Schlemmer KB, Noal CB, Jaques JA, Bagatini MD, Pimentel VC, Carli LF, Leal CA, Fleck J, Moretto MB, Schetinger MR, Leal DB. Purinergic system ecto-enzymes participate in the thromboregulation of patients with indeterminate form of Chagas disease. Purinergic Signal 2012;8:753-762.
235. Ruíz MA, Escriche M, Lluís C, Franco R, Martin M, Andrés A, Ros M. Adenosine A(1) receptor in cultured neurons from rat cerebral cortex: Colocalization with adenosine deaminase. J Neurochem 2000;75:656-664.
236. Dong RP, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, Morimoto C. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 1996;156:1349-1355.
237. Engel M, Hoffmann T, Wagner L, Wermann M, Heiser U, Kiefersauer R, Huber R, Bode W, Demuth HU, Brandstetter H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci USA 2003;100:5063-5068.
238. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 2009;58:1723-1747.
239. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): Knowing the function before inhibiting the enzyme. Curr Med Chem 2009;16:2943-2951.
240. Antonyan AA, Sharoyan SG, Mardanyan SS, Galoyan AA. Proline-rich cytokine from neurosecretory granules: A new natural substrate for dipeptidyl peptidase IV. Neurochem Res 2011;36:34-38.
241. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 2005;198:277-292.
242. Chien CH, Tsai CH, Lin CH, Chou CY, Chen X. Identification of hydrophobic residues critical for DPP-IV dimerization. Biochemistry 2006;45:7006-7012.
243. Chung KM, Cheng JH, Suen CS, Huang CH, Tsai CH, Huang LH, Chen YR, Wang AH, Jiaang WT, Hwang MJ, Chen X. The dimeric transmembrane domain of prolyl dipeptidase DPP-IV contributes to its quaternary structure and enzymatic activities. Protein Sci 2010;19:1627-1638.
244. Shipkova M, Wieland E. Surface markers of lymphocyte activation and markers of cell proliferation. Clin Chim Acta 2012;413:1338-1349.
245. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease. Atherosclerosis 2013;226:305-314.
246. Dong RP, Tachibana K, Hegen M, Munakata Y, Cho D, Schlossman SF, Marimoto C. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 1997;159:6070-6076.
247. Richard E, Arredondo-Vega FX, Santisteban I, Kelly SJ, Patel DD, Hershfield MS. The binding site of human adenosine deaminase for CD26/Dipeptidyl peptidase IV: The Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency. J Exp Med 2000;192:1223-1236.
248. Richard E, Alam SM, Arredondo-Vega FX, Patel DD, Hershfield MS. Clustered charged amino acids of human adenosine deaminase comprise a functional epitope for binding the adenosine deaminase complexing protein CD26/dipeptidyl peptidase IV. J Biol Chem 2002;277:19720-19726.
249. Weihofen WA, Liu J, Reutter W, Saenger W, Fan H. Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J Biol Chem 2004;279:43330-43335.
250. Jeanfavre DD, Woska JR Jr., Pargellis CA, Kennedy CA, Prendergast J, Stearns C, Reilly PL, Barton RW, Bormann BJ. Effect of deoxycoformycin and val-boropro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase. Biochem Pharmacol 1996;52:1757-1765.
251. De Meester I, Vanham G, Kestens L, Vanhoof G, Bosmans E, Gigase P, Scharpe S. Binding of adenosine deaminase to the lymphocyte surface via CD26. Eur J Immunol 1994;24:566-570.
252. Fan H, Tansi FL, Weihofen WA, Böttcher C, Hu J, Martinez J, Saenger W, Reutter W. Molecular mechanism and structural basis of interaction of dipeptidyl peptidase IV with adenosine deaminase and human immunodeficiency virus type-1 transcription transactivator. Eur J Cell Biol 2012;91:265-273.
253. Sharoyan S, Antonyan A, Mardanyan S, Lupidi G, Cristalli G. Influence of dipeptidyl peptidase IV on enzymatic properties of adenosine deaminase. Acta Biochim Pol 2006;53:539-546.
254. Focosi D, Kast RE, Galimberli S, Petrini M. Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex. J Leukoc Biol 2008;84:331-337.
255. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL. Generation and accumulation of immunosuppressive adenosine by human CD4+ CD25 high FOXP3+ regulatory T cells. J Biol Chem 2010;285:7176-7186.
256. Martinez-Navío JM, Climent N, Pacheco R, Garcia F, Plana M, Nomdedeu M, Oliva H, Rovira C, Miralles L, Gatell JM, Gallart T, Mallol J, Lluís C, Franco R. Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation. Immunology 2009;128:393-404.
257. Climent N, Martinez-Navio JM, Gil C, Garcia F, Rovira C, Hurtado C, Miralles L, Gatell JM, Gallart T, Mallol J, Lluis C, Franco R. Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV. Immunol Cell Biol 2009;87:634-639.
258. +T cells. J Leukoc Biol 2011;89:127-136.
259. Casanova V, Naval-Macabuhay I, Massanella M, Rodriguez-Garcia M, Blanco J, Gatell JM, Garcia F, Gallart T, Lluis C, Mallol J, Franco R, Climent N, McCormick PJ. Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals. PLoS One 2012;7:e51287.
260. Martínez-Navío JM, Climent N, Gallart T, Lluís C, Franco R. An old enzyme for current needs: Adenosine deaminase and a dendritic cell vaccine for HIV. Immunol Cell Biol 2012;90:594-600.
261. Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K, Mizutani S. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res 2003;63:2278-2283.
262. Kikkawa F, Kajiyama H, Ino K, Shibata K, Mizutani S. Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV. Int J Cancer 2003;105:779-783.
263. Thompson MA, Ohnuma K, Abe M, Morimoto C, Dang NH. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem 2007;7:253-273.
264. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 2008;13:1634-1645.
265. Stremenova J, Mares V, Lisa V, Hilser M, Krepela E, Vanickova Z, Syrucek M Soula O, Sedo A. Expression of dipeptidyl peptidase-IV activity and / or structure homologs in human meningiomas. Int J Oncol 2010;36:351-358.
266. Kameoka J, Ichinohasama R, Inoue H, Yamamoto J, Yokoyama H, Tomiya Y, Yamada M, Ishizawa K, Harigae H, Sawai T, Sasaki T. CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma. Leuk Lymphoma 2006;47:2181-2188.
267. Ciruela F, Saura C, Canela EI, Mallol J, Lluis C, Franco R. Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett 1996;380:219-223.
268. Saura C, Ciruela F, Casadó V, Canela EI, Mallol J, Lluis C, Franco R. Adenosine deaminase interacts with A1 adenosine receptors in pig brain cortical membranes. J Neurochem 1996;66:1675-1682.
269. Gracia E, Pérez-Capote K, Moreno E, Barkesova J, Mallol J, Lluís C, Franco R, Cortés A, Casadó V, Canela EI. A2A adenosine receptor ligand binding and signalling is allosterically modulated by adenosine deaminase. Biochem J 2011;435:701-709.
270. Herrera C, Casadó V, Ciruela F, Schofield P, Mallol J, Lluis C, Franco R. Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. Mol Pharmacol 2001;59:127-134.
271. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 2000;362:364-374.
272. Wojcik M, Zieleniak A, Wozniak LA. New insight into A1 adenosine receptors in diabetes treatment. Curr Pharm Dev 2010;16:4237-4242.
273. Paul S, Elsinga PH, Ishiwata K, Dierckx RA, van Waarde A. Adenosine A(1) receptors in the central nervous system: Their functions in health and disease, and possible elucidation by PET imaging. Curr Med Chem 2011;18:4820-4835.
274. Ren H, Stiles GL. Characterization of the human A1 adenosine receptor gene. Evidence for alternative splicing. J Biol Chem 1994;269:3104-3110.
275. Rivkees SA, Lasbury ME, Stiles GS, Henegariu O, Curtis C, Vance G. The human A1 adenosine receptor: Ligand binding properties, sites of somatic expression and chromosomal localization. Endocrine 1995;3:623-629.
276. Dixon AK, Guvitz AK, Sirinathsinghji DJS, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1996;118:1461-1468.
277. 11C]MPDX. Ann Nucl Med 2003;17:511-515.
278. Dhalla AK, Chisholm JW, Reaven GM, Belardinelli L. A1 adenosine receptor: Role in diabetes and obesity. Handb Exp Pharmacol 2009;193:271-295.
279. Calzetta L, Spina D, Cazzola M, Page CP, Facciolo F, Rendina EA, Matera MG. Pharmacological characterization of adenosine receptors on isolated human bronchi. Am J Respir Cell Mol Biol 2011;45:1222-1231.
280. Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW. Adenosine: A mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997;276:1265-1268.
281. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001;24:31-55.
282. Florian C, Vecsey CG, Halassa MM, Haydon PG, Abel T. Astrocyte-derived adenosine and A1 receptor activity contribute to sleep loss-induced deficits in hippocampal synaptic plasticity and memory in mice. J Neurosci 2011;31:6956-6962.
283. Huang ZL, Urade Y, Hayaishi O. The role of adenosine in the regulation of the sleep. Curr Top Med Chem 2011;11:1047-1057.
284. Heurteaux C, Lauritzen I, Widmann C, Lazdunski M. Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K+ channels in cerebral ischemic preconditioning. Proc Natl Acad Sci USA 1995;92:4666-4670.
285. Gottlieb SS. Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs 2001;61:1387-1393.
286. 1 adenosine receptor ligands. Curr Top Med Chem 2003;3:369-385.
287. Elzein E, Zablocki J. A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 2008;17:1901-1910.
288. Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antagonists, agonists and allosteric enhancers. Handb Exp Pharmacol 2009;193:25-58.
289. Nell PG, Albrecht-Kupper B. The adenosine A1 receptor and its ligands. Prog Med Chem 2009;47:163-201.
290. Schenone S, Brullo C, Musumeci F, Bruno O, Botta M. A1 receptor ligands: Past, present and future trends. Curr Top Med Chem 2010;10:878-901.
291. Tiller SL, Boucher RC. A1 antagonism in asthma: Better than coffee? J Clin Invest 2005;115:13-16.
292. Hocher B. Adenosine A1 receptor antagonists in clinical research and development. Kidney Int 2010;78:438-445.
293. Vollert C, Forkuo GS, Bond RA, Eriksen JL. Chronic treatment with DPCPX, an adenosine A(1) antagonist, worsens long-term memory. Neurosci Lett 2013;548:296-300.
294. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 2007;83:277-292.
295. 3]GABA release from rat hippocampal nerve terminals. Neuropharmacology 2000;39:1156-1167.
296. Cunha RA, Ferré S, Vaugeois JM, Chen JF. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des 2008;14:1512-1524.
297. Moreau JL, Huber G. Central adenosine A(2A) receptors. An overview. Brain Res Rev 1999;31:65.82.
298. Cristalli G, Müller CE, Volpini R. Recent developments in adenosine A2A receptor ligands. Handb Exp Pharmacol 2009;193:59-98.
299. Brown, RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol 2008;15:S446-S456.
300. Clementina M, Giuseppe S. A2A receptor ligands: Past, present and future trends. Curr Top Med Chem 2010;10:902-922.
301. Zhu X, Shiba H, Fung JJ, Wang LF, Arakawa Y, Irefin S, Demetris AJ, Kelly DM. The role of the A2A receptor agonist, regadenoson, in modulating hepatic artery flow in the porcine small-for-size liver graft. J Surg Res 2012;174:e37-45.
302. Black KJ, Koller JM, Campbell MC, Gusnard DA Bandak SI. Quantification of indirect pathway inhibition by the adenosine A2A antagonist SYN 115 in Parkinson disease. J Neurosci 2010;30:16284-16292.
303. Pinna A, Tronci E, Schintu N, Simola N, Volpini R, Pontis S, Cristalli G, Morelli M. A new ethyl adenine antagonist of adenosine A(2A) receptors: Behavioral and biochemical characterization as an anti-Parkinsonian drug. Neuropharmacology 2010;58:613-623.
304. Shook BC, Jackson PF. Adenosine A(2A) receptor antagonists and Parkinson's disease. ACS Chem Neurosci 2011;2:555-567.
305. Armentero MT, Pinna A, Ferré, S, Lanciego JL, Müller CE, Franco R. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther 2011;132:280-299.
306. Hickey P, Stacy M. Adenosine A2A antagonists in Parkinson's disease: What's next? Curr Neurol Neurosci Rep 2012;12:376-385.
307. Kulisevsky J, Poyurovsky M. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders. Eur Neurol 2012;67:4-11.
308. Popoli P, Pepponi R. Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous system. CNS Neurol Disord Drug Targets 2012;11:664-674.
309. Casetta I, Vincenzi F, Bencivelli D, Corciulo C, Gentile M, Granieri E, Borea PA, Varani K. A2A adenosine receptors and Parkinson's disease severity. Acta Neurol Scand 2013;129:276-281.
310. Muller T. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: Pharmacokinetic and clinical considerations. Expert Opin Drug Metab Toxicol 2013;9:1015-1024.
311. Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 2011;1808:1290-1308.
312. 2B receptor. Biochemistry 2013;52:726-740.
313. 2B adenosine receptor. Biochim Biophys Acta 2014; 1840:1194-1203.
314. Vitzthum H, Weiss B, Bachleitner W, Kramer BK, Kurtz A. Gene expression of adenosine receptors along the nephron. Kidney Int 2004;65:1180-1190.
315. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Adenosine inhibits PDGF-induced growth of human glomerular mesanglial cells via A2B receptors. Hypertension 2005;46:628-634.
316. Johnston-Cox H, Koupenova M, Yang D, Corkey B, Gokce N, Farb MG, LeBrasseur N, Ravid K. The A2b adenosine receptor modulates glucose homeostasis and obesity. PLoS One 2012;7:e40584.
317. Volpini R, Constanzi S, Vittori S, Cristalli G, Klotz KN. Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr Top Med Chem 2003;3:427-443.
318. Hasko G, Csoka B, Nemeth ZH, Vizi ES, Pacher P. A(2B) adenosine receptors in immunity and inflammation. Trends Immunol 2009;30:263-270.
319. Feoktistov I, Biaggioni I. Role of adenosine A(2B) receptors in inflammation. Adv Pharmacol 2011;61:115-144.
320. Schiedel AC, Hinz S, Thimm D, Sherbiny F, Borrmann T, Maass A, Müller CE. The four cysteine residues in the second extracellular loop of the human adenosine A2B receptor: Role in ligand binding and receptor function. Biochem Pharmacol 2011;82:389-399.
321. Wei Q, Constanzi S, Balasubramanian R, Gao ZG, Jacobson KA. A2B adenosine receptor blockade inhibits growth of prostate cancer cells. Purinergic Signal 2013;9:271-280.
322. 2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol 2010;185:542-550.
323. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn MR. Role of A2B adenosine receptor signalling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 2006;116:2173-2182.
324. Karmouty-Quintana H, Zhong H, Acero L, Weng T, Melicoff E, West JD, Hemnes A, Grenz A, Eltzschig HK, Blackwell TS, Xia Y, Johnston RA, Zeng D, Belardinelli L, Blackburn MR. The A2B adenosine receptor modulates pulmonart hypertension associated with interstitial lung disease. FASEB J 2012;26:2546-2557.
325. Sarrió S, Casadó V, Escriche M, Ciruela F, Mallol J, Canela EI, Lluis C, Franco R. The heat shock cognate protein hsc73 assembles with A(1) adenosine receptors to form functional modules in the cell membrane. Mol Cell Biol 2000;20:5164-5174.
326. Sun WC, Cao Y, Jin L, Wang LZ, Meng F, Zhu XZ. Modulating effect of adenosine deaminase on function of adenosine A1 receptors. Acta Pharmacol Sin 2005;26:160-165.
327. 3H] (R)-PIA binding to the caudate nucleus. J Neurochem 2008;107:161-170.
328. Gracia E, Moreno E, Cortes A, Lluis C, Mallol J, McCormick PJ, Canela EI, Casadó V. Homodimerization of adenosine A1 receptors in brain cortex explains the biphasic effects of caffeine. Neuropharmacology 2013;71:56-69.
329. Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Adenosine receptors and cancer. Biochim Biophys Acta 2011;1808:1400-1412.
330. Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets-What are the challenges? Nat Rev Drug Discov 2013;12:265-286.
331. Elsherbiny NM, Al-Gayyar MM. Adenosine receptors: New therapeutic targets for inflammation in diabetic nephropathy. Inflamm Allergy Drug Targets 2013;12:153-161.
332. Headrick JP, Ashton KJ, Rose'meyer RB, Peart JN. Cardiovascular adenosine receptors: Expression, actions and interactions. Pharmacol Ther 2013;140:92-111.
333. Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002;54:323-374.
334. Gao ZG, Jacobson KA. Allosterism in membrane receptors. Drug Discov Today 2006;11:191-202.
335. May LT, Leach K, Sexton PM, Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 2007;47:1-51.
336. Springael JY, Urizar E, Costagliola S, Vassart G, Parmentier M. Allosteric properties of G protein-coupled receptor oligomers. Pharmacol Therapeut 2007;115:410-418.
337. Conn JP, Christopoulos A, Linsley CW. Allosteric modulation of GPCRs: A novel approach for the treatment of CNS disorders. Nature Rev Drug Discovery 2009;8:41-54.
338. De Amici M, Dallanoce C, Holzgrabe U, Tränkle C, Mohr K. Allosteric ligands for G protein-coupled receptors: A novel strategy with attractive therapeutic opportunities. Med Res Rev 2010;30:463-549.
339. Smith NJ, Milligan G. Allostery at G protein-coupled receptor homo- and heteromers: Uncharted pharmacological landscapes. Pharmacol Rev 2010;62:701-725.
340. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, Lindsley CW. Allosteric modulation of seven transmembrane spanning receptors: Theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 2012;55:1445-1464.
341. Christopoulos A. Allosteric binding sites on cell-surface receptors. Novel targets for drug discovery. Nat Rev Drug Discov 2002;1:198-210.
342. May LT, Christopoulos A. Allosteric modulators of G-protein-coupled receptors. Curr Opinion Pharmacol 2003;3:551-556.
343. Bruns RF, Fergus JH. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 1990;38:939-949.
344. Bruns RF, Fergus JH, Coughenour LL, Courtland GG, Pugsley TA, Dodd JH, Tinney FJ. Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. Mol Pharmacol 1990;38:950-958.
345. Nikolakopoulos G, Figler H, Linden J, Scammells PJ. 2-Aminothiophene-3-carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers. Bioorg Med Chem 2006;14:2358-2365.
346. Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A, Scamells PJ. Allosteric modulators of the adenosine A1 receptor: Synthesis and pharmacological evaluation of 4-substituted 2-amnio-3-benzoylthiophenes. J Med Chem 2009;52:4543-4547.
347. Valant C, Aurelio L, Urmaliva VB, White P, Scammells PJ, Sexton PM, Christopoulos A. Delineating the mode of action of adenosine A1 receptor allosteric modulators. Mol Pharmacol 2010;78:444-455.
348. Valant C, Aurelio L, Devine SM, Ashton TD, White JM, Sexton PM, Christopoulos A, Scammells PJ. Synthesis and characterization of novel 2-amino-3benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A1 receptor. J Med Chem 2012;55:2367-2375.
349. Goblyos A, Ijzerman AP. Allosteric modulation of adenosine receptors. Biochim Biophys Acta 2011;1808:1309-1318.
350. Gao ZG, Ijzerman AP. Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions. Biochem Pharmacol 2000;60:669-676.
351. Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D. A2A adenosine receptor and its modulators: Overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. Curr Pharm Des 2008;14:1525-1552.
352. Kreth S, Kaufmann I, Kedderose C, Luchting B, Thiel M. Reduced ligand affinity leads to an impaired function of the adenosine A2A receptor of human granulocytes in sepsis. J Cell Mol Med 2009;13:985-994.
353. Carlsson J, Yoo L, Gao ZG, Irwin JJ, Shoichet BK, Jacobson KA. Structure-based discovery of A2A adenosine receptor ligands. J Med Chem 2010;53:3748-3755.
354. Katritch V, Jaakola VP, Lane JR, Lin J, Ijzerman AP, Yeager M, Kufareva I, Stevens RC, Abagyan R. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem 2010;53:1799-1809.
355. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, Han GW, Roth CB, Heitman LH, Ijzerman AP, Cherezov V, Stevens RC. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 2012;337:232-236.
356. Baraldi PG, Iaconinoto MA, Moorman AR, Carrion MD, Cara CL, Preti D, López OC, Fruttarolo F, Tabrizi MA, Romagnoli R. Allosteric enhancers for A1 adenosine receptor. Mini Rev Med Chem. 2007;7:559-69.
357. Popoli P, Blum D, Martire A, Ledent C, Ceruti S, Abbracchio MP. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog Neurobiol 2007;81:331-348.
358. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF. Adenosine A2A antagonists and Parkinson's disease. Parkinsonism Relat Disord 2009;15:406-413.
359. Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological disease: Neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009;193:535-587.
360. Ernst OP, Gramse V, Kolbe M, Hofmann KP, Heck M. Monomeric G protein-coupled receptor rhodopsin in solution activates its G protein transducin at the diffusion limit. Proc Natl Acad Sci USA 2007;104:10859-10864.
361. Whorton MR, Bokoch MP, Rasmissen SG, Huang B, Zare RN, Kobilka B, Sunahara RK. A monomeric G protein-coupled receptor isolated in a high density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci USA 2007;104:7682-7687.
362. Whorton MR, Jastrzebska B, Park PS, Fotiadis D, Engel A Palcewski K, Sunahara RK. Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J Biol Chem 2008;283:4387-4394.
363. Kuszak AJ, Pitchiaya Anand JP, Mosberg HI, Walter NG, Sunahara RK. Purification and functional reconstitution of monomeric mu-opioid receptors: Allosteric modulation of agonist binding by Gi2. J Biol Chem 2009;284:26732-26741.
364. Carriba P, Navarro G, Ciruela F, Ferré S, Casadó V, Agnati L, Cortés A, Mallol J, Fuxe K, Canela EI, Lluís C, Franco R. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods 2008;5:727-733.
365. Guo W, Urizar E, Kralikova M, Movarec JC, Shi L, Filizola M, Javitch JA. Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J 2008;27:2293-2304.
366. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, George SR, Javitch JA, Lohse MJ, Mackie K, Milligan G, Pfleger KD, Pin JP, Volkow ND, Waldhoer M, Woods AS, Franco R. Building a new conceptual framework for receptor heteromers. Nat Chem Biol 2009;5:131-134.
367. Fung JJ, Deupi X, Pardo L, Yao XJ, Velez-Ruiz GA, Devree BT, Sunahara RK, Kobilka BK. Ligand-regulated oligomerization of beta (2)-adrenoreceptors in a model lípid bilayer. EMBO J 2009;28:3315-3328.
368. Albizu L, Cottet M, Kralikova M, Stoev S, Seyer R, Brabet I, Roux T, Bazin H, Bourrier E, Lamarque L, Breton C, Rives ML, Newman A, Javitch J, Trinquet E, Manning M, Pin JP, Mouillac B, Durroux T. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat Chem Biol 2010;6:587-594.
369. Ferré S, Franco R. Oligomerization of G-protein-coupled receptors: A reality. Curr Opin Pharmacol 2010;10:1-5.
370. Lohse MJ. Dimerization in GPCR mobility and signalling. Curr Opin Pharmacol 2010;10:53-58.
371. Fanelli F, Felline A. Dimerization and ligand binding affect the structure network of A2A adenosine receptor. Biochim Biophys Acta 2011;1808:1256-1266.
372. Ganguly S, Clayton AHA, Chattopadhyay A. Organization of higher order oligomers of the serotonin 1A receptor explored utilizing homo-FRET in live cells. Biophys J 2011;100:361-368.
373. Rozenfeld R, Devi LA. Exploring a role for heteromerization in GPCR signalling specificity. Biochem J 2011;433:11-18.
374. Selent J, Kaczor AA. Oligomerization of G protein-coupled receptors. Computational methods. Curr Med Chem 2011;18:4588-4605.
375. 1A receptor. Mol Pharmacol 2012;82:448-463.
376. Roed SN, Orgaard A, Jorgensen R, De Meyts P. Receptor oligomerization in family B1 of G-protein-coupled receptors: Focus on BRET investigations and the link between GPCR oligomerization and binding cooperativity. Front Endocrinol 2012;3:62.
377. 2C) receptor revealed by fluorescence correlation spectroscopy with photon counting histogram analysis. Evidence for homodimers without monomers or tetramers. J Biol Chem 2012;287:23604-23614.
378. Herrick-Davis K, Grinde E, Cowan A, Mazurkiewicz JE. Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic and dopamine receptor dimerization: The oligomer number puzzle. Mol Pharmacol 2013;84:630-642.
379. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, Pardo L, Weiss WI, Kobilka BK, Granier S. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 2012;485:321-326.
380. Canals M, Burgueño J, Marcellino D, Cabello N, Canela EI, Mallol J, Agnati L, Ferré S, Bouvier M, Fuxe K, Ciruela F, Lluís C, Franco R. Homodimerization of adenosine A2A receptors: Qualitative and quantitative assessment by fluorescence and bioluminiscence energy transfer. J Neurochem 2004;88:726-734.
381. Franco R, Casadó V, Mallol J, Ferré S, Fuxe K, Cortés A, Ciruela F, Lluís C, Canela EI. Dimer-based model for heptaspaning membrane receptors. Trends Biochem Sci 2005;30:360-366.
382. Durroux T. Principles: A model for the allosteric interactions between ligand binding sites within a dimeric GPCR. Trends Pharmacol Sci 2005;26:376-384.
383. Albizu L, Balestre MN, Breton C, Pin JP, Manning M, Mouillac B, Barberis C, Durroux T. Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding. Mol Pharmacol 2006;70:1783-1791.
384. Casadó V, Cortés A, Ciruela F, Mallol J, Ferré S, Lluís C, Canela EI, Franco R. Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monoméric and dimeric receptors: The receptor-dimer cooperativity index. Pharmacol Ther 2007;116:343-354.
385. Franco R, Casadó V, Mallol J, Ferrada C, Ferré S, Fuxe K, Cortés A, Ciruela F, Lluís C, Canela EI. The two-state dimer receptor model: A general model for receptor dimers. Mol Pharmacol 2006;69:1905-1912.
386. Casadó V, Ferrada C, Bonaventura J, Gracia E, Mallol J, Canela EI, Lluís C, Cortés A, Franco R. Useful pharmacological parameters for G-protein-coupled receptor homodimers obtained from competition experiments. Agonist-antagonist binding modulation. Biochem Pharmacol 2009;78:1456-1463.
387. Casadó V, Cortés A, Mallol J, Pérez-Capote K, Ferré S, Lluís C, Franco R, Canela EI. GPCR homomers and heteromers: A better choice as targets for drug development than GPCR monomers? Pharmacol Ther 2009;124:248-257.
388. 1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology 2005;179:576-586.
389. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, Stevens RC. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008;322:1211-1217.
390. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, Stevens RC. Structure of an agonist-bound human A2A adenosine receptor. Science 2011;332:322-327.
391. Doré AS, Robertson N, Errey JC, Ng I, Hollenstein K, Tehan B, Hurrell E, Bennett K, Congreve M, Magnani F, Tate CG, Weir M, Marshall FH. Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 2011;19:1283-1293.
392. Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AG, Tate CG. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 2011;474:521-525.
393. Gracia E, Farré D, Cortés A, Ferrer-Costa C, Orozco M, Mallol J, Lluis C, Canela EI, McCormick PJ, Franco R, Fanelli F, Casadó V. The catalytic site structural gate of adenosine deaminase allosterically modulates ligand binding to adenosine receptors. FASEB J 2013;27:1048-1061.
394. Copley SD. Moonlighting is mainstream: Paradigm adjustment required. Bioessays 2012;34:578-588.
395. Jeffery CJ. Moonlighting proteins. Trends Biochem Sci 1999;24:8-11.
396. Huberts DH, Van der Klei IJ. Moonlighting proteins: An intriguing mode of multitasking. Biochim Biophys Acta 2010;1803:520-525.
397. Jeffery CJ. Moonlighting proteins-an update. Mol Bio Syst 2009;5:345-350.
398. Ovadi J. Moonlighting proteins in neurological disorders. IUBMB Life 2011;63:453-456.